Synthesis and Preclinical Evaluation of [11C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor

被引:3
|
作者
Dahl, Kenneth [1 ,4 ]
Johnstrom, Peter [2 ,3 ]
Forsberg-Moren, Anton [2 ]
Gustafsson, Bjorn [2 ]
Miranda-Azpiazu, Patricia [2 ]
Khani, Yaser [2 ]
Halldin, Christer [2 ]
Farde, Lars
Elmore, Charles S. [5 ]
Schou, Magnus [2 ,3 ]
机构
[1] Karolinska Univ Hosp, Dept Radiopharm, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Karolinska Hosp, Ctr Psychiat Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden
[3] Karolinska Inst, Precis Med & Biosamples, AstraZeneca, PET Sci Ctr, S-17176 Stockholm, Sweden
[4] Kaolinska Inst, Dept Oncol & Pathol, SE-17176 Stockholm, Sweden
[5] AstraZeneca, Early Chem Dev, Pharmaceut Sci, R&D,Isotope Chem, S-43150 Molndal, Sweden
来源
ACS CHEMICAL NEUROSCIENCE | 2022年 / 13卷 / 14期
关键词
  PET imaging; radioligand; receptor; serotonin; carbon-11; 5-HT; 1A; 5-HT1A RECEPTORS; HUMAN BRAIN; RADIOLIGAND; BINDING; VISUALIZATION; DEPRESSION; MONKEY;
D O I
10.1021/acschemneuro.2c00205
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ABSTRACT: The serotonin 1A (5-HT1A) receptor is a G-proteincoupled receptor implicated in the pathophysiology of several neuropsychiatric and neurodegenerative disorders. We here report the preparation of two candidate 5-HT1A radioligands, [11C]AZ11132132 ([11C]3) and [11C]AZ11895530 ([11C]4), and their subsequent evaluation in vitro using autoradiography and in vivo using positron emission tomography (PET). Compounds 3 and 4 were radiolabeled at high radiochemical purity (>99%) and high molar activity (>38 GBq/mu mol) by heteroatom methylation with [11C]methyl iodide. Autoradiography on whole hemispheres from post-mortem human brain revealed substantial nonspecific binding of [11C]3, while the binding of [11C]4 to brain tissue was consistent with the distribution of 5-HT1A receptors and sensitive to co-incubation with the reference 5-HT1A antagonist WAY100635 (10 mu M). Following intravenous injection of [11C]4 into a cynomolgus monkey, brain radioactivity concentration (Cmax similar to 2.2 SUV) was high whereafter it decreased rapidly. The regional binding potential (BPND) values were calculated using the simplified reference tissue model with cerebellum as reference region. The values varied between 0.2 and 1.0 for temporal cortex, raphe nuclei, frontal cortex, and hippocampus which is consistent with the known 5-HT1A expression pattern. After pretreatment with WAY100635 (0.5 mg/kg), a homogeneous distribution of radioactivity was observed in non-human primate (NHP) brain. Although [11C]4 fulfilled important criteria for successful in vivo neuroimaging, including good blood-brain-barrier permeability and high specific binding in vitro to human brain tissue, the regional BPND values for [11C]4 in NHP brain were low when compared to those obtained with existing radioligands and thus do not merit further investigation of [11C]4. Evaluation of structurally related analogues is underway in our laboratory to identify improved candidates for clinical imaging.
引用
收藏
页码:2078 / 2083
页数:6
相关论文
共 50 条
  • [21] Evaluation of [11C]methyl-losartan and [11C]methyl-EXP3174 for PET imaging of renal AT1 receptor in rats
    Ismail, Basma
    Hadizad, Tayebeh
    Antoun, Rawad
    Lortie, Mireille
    deKemp, Robert A.
    Beanlands, Rob S. B.
    DaSilva, Jean N.
    NUCLEAR MEDICINE AND BIOLOGY, 2015, 42 (11) : 850 - 857
  • [22] Synthesis and preclinical evaluation of serotonin 5-HT6 receptor radioligands for PET imaging
    Becker, G.
    Colomb, J.
    Billard, T.
    Zimmer, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S198 - S198
  • [23] [11C]-NS 4194 versus [11C]-DASB for PET imaging of serotonin transporters in living porcine brain
    Jensen, SB
    Smith, DF
    Bender, D
    Jakobsen, S
    Peters, D
    Nielsen, EO
    Olsen, GM
    Scheel-Krüger, J
    Wilson, A
    Cumming, P
    SYNAPSE, 2003, 49 (03) : 170 - 177
  • [24] β-amyloid Imaging Agents for PET - Preclinical Evaluation of [11C]PIB and [18F]Flutemetamol
    Pakkanen, A.
    Rokka, J.
    Wilson, I.
    Farrar, G.
    Solin, O.
    Rinne, J. O.
    Haaparanta, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S396 - S396
  • [25] Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer
    Evens, Nele
    Vandeputte, Caroline
    Coolen, Charlotte
    Janssen, Peter
    Sciot, Raf
    Baekelandt, Veerle
    Verbruggen, Alfons M.
    Debyser, Zeger
    Van Laere, Koen
    Bormans, Guy M.
    NUCLEAR MEDICINE AND BIOLOGY, 2012, 39 (03) : 389 - 399
  • [26] Improved methodology for measurement of serotonin release using [11C]AZ10419369 and PET
    Finnema, S. J.
    Varrone, A.
    Hwang, T.
    Farde, L.
    Halldin, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S249 - S249
  • [27] Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil
    Verbeek, Joost
    Syvanen, Stina
    Schuit, Robert C.
    Eriksson, Jonas
    de Lange, Elizabeth C.
    Windhorst, Albert D.
    Luurtsema, Gert
    Lammertsma, Adriaan A.
    NUCLEAR MEDICINE AND BIOLOGY, 2012, 39 (04) : 530 - 539
  • [28] Synthesis and evaluation of [11C]propiverine as radiotracer for PET imaging of muscarinic acetylcholine receptors
    Wuensche, Thomas
    Bailey, Justin J.
    Wuest, Melinda
    Wuest, Frank
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S42 - S42
  • [29] An updated synthesis of [11C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor
    Blecha, Joseph E.
    Henderson, Bradford D.
    Hockley, Brian G.
    VanBrocklin, Henry F.
    Zubieta, Jon-Kar
    DaSilva, Alexandre F.
    Kilbourn, Michael R.
    Koeppe, Robert A.
    Scott, Peter J. H.
    Shao, Xia
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 (08): : 375 - 380
  • [30] Synthesis and Initial In Vivo Evaluation of [11C]AZ683-A Novel PET Radiotracer for Colony Stimulating Factor 1 Receptor (CSF1R)
    Tanzey, Sean S.
    Shao, Xia
    Stauff, Jenelle
    Arteaga, Janna
    Sherman, Phillip
    Scott, Peter J. H.
    Mossine, Andrew, V
    PHARMACEUTICALS, 2018, 11 (04)